Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

Blood Cancer J. 2023 Feb 20;13(1):29. doi: 10.1038/s41408-023-00801-1.

Authors

Kathryn T Maples¹, Kevin H Hall², Nisha S Joseph², Craig C Hofmeister², Vikas Gupta², Madhav V Dhodapkar², Jonathan L Kaufman², Ajay K Nooka², Sagar Lonial²

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. [email protected].
² Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Multiple Myeloma*

Substances

daratumumab
Antibodies, Monoclonal